Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection
Open Access
- 1 January 2010
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 138 (1) , 123-135.e2
Abstract
No abstract availableKeywords
Funding Information
- National Health and Medical Research Council
- National Institutes of Health (RO1 DA 15999-01)
- Department of Health and Ageing, Australian Government
- VicHealth
- University of New South Wales
- Canadian Institutes of Health Research
This publication has 27 references indexed in Scilit:
- Characteristics and Treatment Outcomes among HIV‐Infected Individuals in the Australian Trial in Acute Hepatitis CClinical Infectious Diseases, 2009
- Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic ResponseGastroenterology, 2006
- Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis CJournal of Antimicrobial Chemotherapy, 2006
- Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studiesJournal of Viral Hepatitis, 2005
- The short‐form version of the Depression Anxiety Stress Scales (DASS‐21): Construct validity and normative data in a large non‐clinical sampleBritish Journal of Clinical Psychology, 2005
- Efficacy of a 24-week course of PEG-interferon α-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearanceJournal of Hepatology, 2005
- Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis CJournal of Hepatology, 2005
- When and how to treat acute hepatitis C?Journal of Hepatology, 2003
- Natural history of chronic hepatitis CHepatology, 2002
- Treatment of Acute Hepatitis C with Interferon Alfa-2bNew England Journal of Medicine, 2001